article · Anti-Cancer Agents in Medicinal Chemistry
INTRODUCTION: Hepatocellular Carcinoma (HCC) is a leading cause of cancer death with limited responsiveness to radiotherapy. β-Carotene has chemopreventive properties, but its clinical use is hindered by poor aqueous solubility and instability. This study developed PEGylated β-carotene-loaded liposomes (PEGLipo- β-Car) as a novel nanocarrier-based radiosensitizer and used in silico modeling to explore its molecular interactions. METHODS: PEG-Lipo-β-Car was prepared via thin-film hydration and characterized (TEM, DLS, FTIR, DSC). Cytotoxicity and radiosensitization were evaluated in HepG2 cells under γ-irradiation (0, 5, 10 Gy) using MTT assays, with synergy quantified via Combination Indices (CI). Molecular docking assessed β-carotene binding to PARP and ATM. RESULTS: PEG-Lipo-β-Car exhibited good colloidal stability (size: 143.4 ± 8.2 nm, PDI: 0.201, EE >94%). At 10 Gy irradiation, it reduced the IC50 from 29.78 to 0.57 μg/mL, a 52-fold enhancement with strong synergy (CI=0.019). Empty liposomes alone conferred significant radiosensitization (~30-fold). Docking revealed β- carotene binds the catalytic sites of PARP (-9.19 ± 0.37 kcal/mol) and ATM (-10.12 ± 0.36 kcal/mol). DISCUSSION: The observed radiobiological synergy may stem from a combined effect of carrier-mediated membrane perturbation and/or ROS amplification, coupled with the potential inhibition of DNA repair pathways by the delivered β-carotene. CONCLUSIONS: PEGylation enhances β-carotene's stability and radiosensitizing efficacy in HCC cells through a combined mechanism involving carrier effects and potential interference with PARP- and ATM-mediated DNA repair. PEG-Lipo-β-Car is a promising candidate for future preclinical evaluation in hepatocellular carcinoma radiotherapy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2174/0118715206430772260121073200
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.